Why oncology needs dosing redesign.
Sirj Goswami, PhD
Advertisement
Sirj Goswami, PhD, CEO, co-founder of InsightRX
Articles by Sirj Goswami, PhD
Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.
Advertisement
Latest Updated Articles
Understanding Project OptimusPublished: July 13th 2022 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
2
Reducing Site Burden Through Better Technology Integration in Clinical Trials
3
ACT Brief: AI, Equity, and Innovation Drive Clinical Research Forward
4
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
